Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 5Lymphoid 4Breast 4Thoracic 3Other solid neoplasm 3Myeloid 2Head & Neck 2Gastrointestinal 2Dermatologic 2Sarcoma 1Plasma cell 1Gynecologic 1Genitourinary 1Endocrine 1Classical hematology 1CNS 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Anemia 1

Interventions

Cyclophosphamide 37fludarabine phosphate 35Mycophenolic Acid 33Whole-Body Irradiation 32Busulfan 24Tacrolimus 22fludarabine 21Peripheral Blood Stem Cell Transplantation 20Cyclosporine 20Melphalan 17Antilymphocyte Serum 13Methotrexate 12Filgrastim 12Granulocyte Colony-Stimulating Factor 11Cytarabine 11Cord Blood Stem Cell Transplantation 11Thiotepa 9thymoglobulin 8eltrombopag 8Lenalidomide 7Etoposide 7Epoetin Alfa 7Dalteparin 7romiplostim 6Darbepoetin alfa 6Alemtuzumab 6merphos 5apixaban 5Sirolimus 5Radiotherapy 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Pharmacogenomic Testing × Classical hematology × Clear all
NCT02048813 2026-05-29

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
529 enrolled 12 charts 1 FDA
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡